Stock Track | Moderna Plummets 5.05% as Argus Downgrades Stock on Weak COVID-19 Vaccine Sales and Growth Concerns

Stock Track12-19

Moderna Inc. (MRNA) stock plummeted 5.05% on Wednesday, following an analyst downgrade from Argus Research citing declining sales of the company's COVID-19 vaccine and limited near-term growth prospects.

The brokerage firm downgraded Moderna's stock rating to "hold" from "buy," noting that while the company's COVID-19 vaccine was a strong performer during the pandemic, sales have dropped significantly as the virus entered a new phase.

Argus also highlighted challenges for Moderna's recently approved respiratory syncytial virus (RSV) vaccine, which was approved more than a year after competing products, potentially limiting its sales as doctors had already become accustomed to other options.

While Moderna has an extensive pipeline of 36 mRNA development candidates across 45 programs, Argus cautioned that these require significant investment and time to reach the market, limiting the company's near-term growth potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116098363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116098363","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Plummets 5.05% as Argus Downgrades Stock on Weak COVID-19 Vaccine Sales and Growth Concerns","media":"Stock Track","content":"<p>Moderna Inc. (MRNA) stock plummeted 5.05% on Wednesday, following an analyst downgrade from Argus Research citing declining sales of the company's COVID-19 vaccine and limited near-term growth prospects.</p>\n\n<p>The brokerage firm downgraded Moderna's stock rating to \"hold\" from \"buy,\" noting that while the company's COVID-19 vaccine was a strong performer during the pandemic, sales have dropped significantly as the virus entered a new phase.</p>\n\n<p>Argus also highlighted challenges for Moderna's recently approved respiratory syncytial virus (RSV) vaccine, which was approved more than a year after competing products, potentially limiting its sales as doctors had already become accustomed to other options.</p>\n\n<p>While Moderna has an extensive pipeline of 36 mRNA development candidates across 45 programs, Argus cautioned that these require significant investment and time to reach the market, limiting the company's near-term growth potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Plummets 5.05% as Argus Downgrades Stock on Weak COVID-19 Vaccine Sales and Growth Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Plummets 5.05% as Argus Downgrades Stock on Weak COVID-19 Vaccine Sales and Growth Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-19 04:40 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) stock plummeted 5.05% on Wednesday, following an analyst downgrade from Argus Research citing declining sales of the company's COVID-19 vaccine and limited near-term growth ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1116098363","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116098363","pubTimestamp":1734554459,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna Inc.  stock plummeted 5.05% on Wednesday, following an analyst downgrade from Argus Research citing declining sales of the company's COVID-19 vaccine and limited near-term growth prospects.The brokerage firm downgraded Moderna's stock rating to \"hold\" from \"buy,\" noting that while the company's COVID-19 vaccine was a strong performer during the pandemic, sales have dropped significantly as the virus entered a new phase.Argus also highlighted challenges for Moderna's recently approved res","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"由于COVID-19疫苗销售疲软和增长担忧，Argus下调股票评级，Moderna股价暴跌5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna Inc. (MRNA) stock plummeted 5.05% on Wednesday, following an analyst downgrade from Argus Research citing declining sales of the company's COVID-19 vaccine and limited near-term growth prospects.\nThe brokerage firm downgraded Moderna's stock rating to \"hold\" from \"buy,\" noting that while the company's COVID-19 vaccine was a strong performer during the pandemic, sales have dropped significantly as the virus entered a new phase.\nArgus also highlighted challenges for Moderna's recently approved respiratory syncytial virus (RSV) vaccine, which was approved more than a year after competing products, potentially limiting its sales as doctors had already become accustomed to other options.\nWhile Moderna has an extensive pipeline of 36 mRNA development candidates across 45 programs, Argus cautioned that these require significant investment and time to reach the market, limiting the company's near-term growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116098363"}